LINE-1 methylation status correlates significantly to post-therapeutic recurrence in stage III colon cancer patients receiving FOLFOX-4 adjuvant chemotherapy

Yun Ting Lou, Chao Wen Chen, Yun Ching Fan, Wei Chiao Chang, Chien Yu Lu, I. Chen Wu, Wen Hung Hsu, Ching Wen Huang, Jaw Yuan Wang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Methylation levels of long interspersed nucleotide elements (LINE-1) are representative of genome-wide methylation status and crucial in maintaining genomic stability and expression. Their prognostic impact on colon cancer patients receiving adjuvant chemotherapy has not been well established. We evaluated the association between LINE-1 methylation status and clinicopathologic features and postoperative oncological outcomes in stage III colon cancer patients. Materials and Methods: 129 UICC stage III colon cancer patients who had received radical resection and FOLFOX adjuvant chemotherapy were enrolled. Global methylation was estimated by analyzing tumor LINE-1 methylation status using bisulfite-polymerase chain reaction (PCR) and pyrosequencing assay. Demographics, clinicopathological data, and postoperative outcomes were recorded by trained abstractors. Outcome measurements included postoperative recurrence and disease-free survival. Univariate, multivariate, and survival analyses were conducted to identify prognostic factors of oncological outcomes. Results: The LINE-1 methylation of all 129 patients was measured on a 0-100 scale (mean 63.3; median 63.7, standard deviation 7.1), LINE-1 hypomethylation was more common in patients aged 65 years and above (61.7%±7.6% vs. 64.6±6.4, p=0.019) and those with post-therapeutic recurrence (61.7±7.4 vs 64.3±6.7, p=0.041). Considering risk adjustment, LINE-1 hypomethylation was found to be an independent risk factor of post-therapeutic recurrence (Adjusted OR=14.1, p=0.012). Kaplan-Meier analysis indicated that patients in the low methylation group had shorter period of disease free survival (p=0.01). In a stratified analysis that included 48 patients with post-therapeutic recurrence, it was found that those who experienced shorter period of disease free survival (蠆6 months) appeared to have lower LINE-1 methylation levels than patients who reported of recurrence after 6 months (56.68±15.75 vs. 63.55±7.57, p=0.041). Conclusion: There was a significantly greater risk of early postoperative recurrence and a shorter period of disease-free survival in Stage III colon cancer patients exhibiting LINE-1 hypomethylation status after being treated with radical resection and FOLFOX chemotherapy.

Original languageEnglish
Article numbere0123973
JournalPLoS One
Volume10
Issue number4
DOIs
Publication statusPublished - Apr 28 2015

Fingerprint

Methylation
Chemotherapy
Adjuvant Chemotherapy
colorectal neoplasms
methylation
Colonic Neoplasms
drug therapy
adjuvants
Recurrence
therapeutics
Disease-Free Survival
Therapeutics
resection
Long Interspersed Nucleotide Elements
Risk Adjustment
bisulfites
Polymerase chain reaction
Genomic Instability
Kaplan-Meier Estimate
Survival Analysis

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

LINE-1 methylation status correlates significantly to post-therapeutic recurrence in stage III colon cancer patients receiving FOLFOX-4 adjuvant chemotherapy. / Lou, Yun Ting; Chen, Chao Wen; Fan, Yun Ching; Chang, Wei Chiao; Lu, Chien Yu; Wu, I. Chen; Hsu, Wen Hung; Huang, Ching Wen; Wang, Jaw Yuan.

In: PLoS One, Vol. 10, No. 4, e0123973, 28.04.2015.

Research output: Contribution to journalArticle

Lou, Yun Ting ; Chen, Chao Wen ; Fan, Yun Ching ; Chang, Wei Chiao ; Lu, Chien Yu ; Wu, I. Chen ; Hsu, Wen Hung ; Huang, Ching Wen ; Wang, Jaw Yuan. / LINE-1 methylation status correlates significantly to post-therapeutic recurrence in stage III colon cancer patients receiving FOLFOX-4 adjuvant chemotherapy. In: PLoS One. 2015 ; Vol. 10, No. 4.
@article{5176c8651d724ce09c8224abdaa2b665,
title = "LINE-1 methylation status correlates significantly to post-therapeutic recurrence in stage III colon cancer patients receiving FOLFOX-4 adjuvant chemotherapy",
abstract = "Background: Methylation levels of long interspersed nucleotide elements (LINE-1) are representative of genome-wide methylation status and crucial in maintaining genomic stability and expression. Their prognostic impact on colon cancer patients receiving adjuvant chemotherapy has not been well established. We evaluated the association between LINE-1 methylation status and clinicopathologic features and postoperative oncological outcomes in stage III colon cancer patients. Materials and Methods: 129 UICC stage III colon cancer patients who had received radical resection and FOLFOX adjuvant chemotherapy were enrolled. Global methylation was estimated by analyzing tumor LINE-1 methylation status using bisulfite-polymerase chain reaction (PCR) and pyrosequencing assay. Demographics, clinicopathological data, and postoperative outcomes were recorded by trained abstractors. Outcome measurements included postoperative recurrence and disease-free survival. Univariate, multivariate, and survival analyses were conducted to identify prognostic factors of oncological outcomes. Results: The LINE-1 methylation of all 129 patients was measured on a 0-100 scale (mean 63.3; median 63.7, standard deviation 7.1), LINE-1 hypomethylation was more common in patients aged 65 years and above (61.7{\%}±7.6{\%} vs. 64.6±6.4, p=0.019) and those with post-therapeutic recurrence (61.7±7.4 vs 64.3±6.7, p=0.041). Considering risk adjustment, LINE-1 hypomethylation was found to be an independent risk factor of post-therapeutic recurrence (Adjusted OR=14.1, p=0.012). Kaplan-Meier analysis indicated that patients in the low methylation group had shorter period of disease free survival (p=0.01). In a stratified analysis that included 48 patients with post-therapeutic recurrence, it was found that those who experienced shorter period of disease free survival (蠆6 months) appeared to have lower LINE-1 methylation levels than patients who reported of recurrence after 6 months (56.68±15.75 vs. 63.55±7.57, p=0.041). Conclusion: There was a significantly greater risk of early postoperative recurrence and a shorter period of disease-free survival in Stage III colon cancer patients exhibiting LINE-1 hypomethylation status after being treated with radical resection and FOLFOX chemotherapy.",
author = "Lou, {Yun Ting} and Chen, {Chao Wen} and Fan, {Yun Ching} and Chang, {Wei Chiao} and Lu, {Chien Yu} and Wu, {I. Chen} and Hsu, {Wen Hung} and Huang, {Ching Wen} and Wang, {Jaw Yuan}",
year = "2015",
month = "4",
day = "28",
doi = "10.1371/journal.pone.0123973",
language = "English",
volume = "10",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - LINE-1 methylation status correlates significantly to post-therapeutic recurrence in stage III colon cancer patients receiving FOLFOX-4 adjuvant chemotherapy

AU - Lou, Yun Ting

AU - Chen, Chao Wen

AU - Fan, Yun Ching

AU - Chang, Wei Chiao

AU - Lu, Chien Yu

AU - Wu, I. Chen

AU - Hsu, Wen Hung

AU - Huang, Ching Wen

AU - Wang, Jaw Yuan

PY - 2015/4/28

Y1 - 2015/4/28

N2 - Background: Methylation levels of long interspersed nucleotide elements (LINE-1) are representative of genome-wide methylation status and crucial in maintaining genomic stability and expression. Their prognostic impact on colon cancer patients receiving adjuvant chemotherapy has not been well established. We evaluated the association between LINE-1 methylation status and clinicopathologic features and postoperative oncological outcomes in stage III colon cancer patients. Materials and Methods: 129 UICC stage III colon cancer patients who had received radical resection and FOLFOX adjuvant chemotherapy were enrolled. Global methylation was estimated by analyzing tumor LINE-1 methylation status using bisulfite-polymerase chain reaction (PCR) and pyrosequencing assay. Demographics, clinicopathological data, and postoperative outcomes were recorded by trained abstractors. Outcome measurements included postoperative recurrence and disease-free survival. Univariate, multivariate, and survival analyses were conducted to identify prognostic factors of oncological outcomes. Results: The LINE-1 methylation of all 129 patients was measured on a 0-100 scale (mean 63.3; median 63.7, standard deviation 7.1), LINE-1 hypomethylation was more common in patients aged 65 years and above (61.7%±7.6% vs. 64.6±6.4, p=0.019) and those with post-therapeutic recurrence (61.7±7.4 vs 64.3±6.7, p=0.041). Considering risk adjustment, LINE-1 hypomethylation was found to be an independent risk factor of post-therapeutic recurrence (Adjusted OR=14.1, p=0.012). Kaplan-Meier analysis indicated that patients in the low methylation group had shorter period of disease free survival (p=0.01). In a stratified analysis that included 48 patients with post-therapeutic recurrence, it was found that those who experienced shorter period of disease free survival (蠆6 months) appeared to have lower LINE-1 methylation levels than patients who reported of recurrence after 6 months (56.68±15.75 vs. 63.55±7.57, p=0.041). Conclusion: There was a significantly greater risk of early postoperative recurrence and a shorter period of disease-free survival in Stage III colon cancer patients exhibiting LINE-1 hypomethylation status after being treated with radical resection and FOLFOX chemotherapy.

AB - Background: Methylation levels of long interspersed nucleotide elements (LINE-1) are representative of genome-wide methylation status and crucial in maintaining genomic stability and expression. Their prognostic impact on colon cancer patients receiving adjuvant chemotherapy has not been well established. We evaluated the association between LINE-1 methylation status and clinicopathologic features and postoperative oncological outcomes in stage III colon cancer patients. Materials and Methods: 129 UICC stage III colon cancer patients who had received radical resection and FOLFOX adjuvant chemotherapy were enrolled. Global methylation was estimated by analyzing tumor LINE-1 methylation status using bisulfite-polymerase chain reaction (PCR) and pyrosequencing assay. Demographics, clinicopathological data, and postoperative outcomes were recorded by trained abstractors. Outcome measurements included postoperative recurrence and disease-free survival. Univariate, multivariate, and survival analyses were conducted to identify prognostic factors of oncological outcomes. Results: The LINE-1 methylation of all 129 patients was measured on a 0-100 scale (mean 63.3; median 63.7, standard deviation 7.1), LINE-1 hypomethylation was more common in patients aged 65 years and above (61.7%±7.6% vs. 64.6±6.4, p=0.019) and those with post-therapeutic recurrence (61.7±7.4 vs 64.3±6.7, p=0.041). Considering risk adjustment, LINE-1 hypomethylation was found to be an independent risk factor of post-therapeutic recurrence (Adjusted OR=14.1, p=0.012). Kaplan-Meier analysis indicated that patients in the low methylation group had shorter period of disease free survival (p=0.01). In a stratified analysis that included 48 patients with post-therapeutic recurrence, it was found that those who experienced shorter period of disease free survival (蠆6 months) appeared to have lower LINE-1 methylation levels than patients who reported of recurrence after 6 months (56.68±15.75 vs. 63.55±7.57, p=0.041). Conclusion: There was a significantly greater risk of early postoperative recurrence and a shorter period of disease-free survival in Stage III colon cancer patients exhibiting LINE-1 hypomethylation status after being treated with radical resection and FOLFOX chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84928779314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928779314&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0123973

DO - 10.1371/journal.pone.0123973

M3 - Article

C2 - 25919688

AN - SCOPUS:84928779314

VL - 10

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0123973

ER -